Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Delarue

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Cancer Research|February 7, 2007
Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartmentsYves Lepelletier, Valérie Camara-Clayette, Hulin Jin, et al.
Blood Advances|June 23, 2022
Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trialVincent Camus, Aurélien Belot, Lucie Oberic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemiaEmmanuel Raffoux, Philippe Rousselot, Jöel Poupon, et al.
Medicine|March 18, 2008
The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patientsBenjamin Terrier, Arnaud Jaccard, Jean-Luc Harousseau, et al.
The Lancet. Oncology|April 13, 2011
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trialFrédéric Peyrade, Fabrice Jardin, Catherine Thieblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA TrialClémentine Sarkozy, Marek Trneny, Luc Xerri, et al.
The Lancet. Haematology|January 3, 2017
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA groupFrédéric Peyrade, Serge Bologna, Vincent Delwail, et al.
Cancer Reports (Hoboken, N.J.)|July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trialCarla Casulo, Armando Santoro, Guillaume Cartron, et al.
The Lancet. Oncology|April 13, 2013
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trialRichard Delarue, Hervé Tilly, Nicolas Mounier, et al.
Blood|April 26, 2003
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trialStefan Suciu, Franco Mandelli, Theo de Witte, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Cancer Research|February 7, 2007
Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartmentsYves Lepelletier, Valérie Camara-Clayette, Hulin Jin, et al.
Blood Advances|June 23, 2022
Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trialVincent Camus, Aurélien Belot, Lucie Oberic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemiaEmmanuel Raffoux, Philippe Rousselot, Jöel Poupon, et al.
Medicine|March 18, 2008
The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patientsBenjamin Terrier, Arnaud Jaccard, Jean-Luc Harousseau, et al.
The Lancet. Oncology|April 13, 2011
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trialFrédéric Peyrade, Fabrice Jardin, Catherine Thieblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2016
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA TrialClémentine Sarkozy, Marek Trneny, Luc Xerri, et al.
The Lancet. Haematology|January 3, 2017
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA groupFrédéric Peyrade, Serge Bologna, Vincent Delwail, et al.
Cancer Reports (Hoboken, N.J.)|July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trialCarla Casulo, Armando Santoro, Guillaume Cartron, et al.
The Lancet. Oncology|April 13, 2013
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trialRichard Delarue, Hervé Tilly, Nicolas Mounier, et al.
Blood|April 26, 2003
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trialStefan Suciu, Franco Mandelli, Theo de Witte, et al.
Pageof 9